Exelixis
EXEL
#1671
Rank
โ‚น840.91 B
Marketcap
โ‚น2,945
Share price
-0.46%
Change (1 day)
66.05%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : โ‚น57.79 Billion

According to Exelixis's latest financial reports the company's total liabilities are โ‚น57.79 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31โ‚น56.47 B17.06%
2022-12-31โ‚น48.24 B59.81%
2021-12-31โ‚น30.19 B59.87%
2020-12-31โ‚น18.88 B32.61%
2019-12-31โ‚น14.24 B51.05%
2018-12-31โ‚น9.42 B-60.13%
2017-12-31โ‚น23.64 B-31.29%
2016-12-31โ‚น34.41 B9.45%
2015-12-31โ‚น31.44 B13.24%
2014-12-31โ‚น27.76 B2.83%
2013-12-31โ‚น27.00 B16.12%
2012-12-31โ‚น23.25 B45.24%
2011-12-31โ‚น16.00 B-39.36%
2010-12-31โ‚น26.39 B12.18%
2009-12-31โ‚น23.53 B6.92%
2008-12-31โ‚น22.00 B71.7%
2007-12-31โ‚น12.81 B-5.05%
2006-12-31โ‚น13.49 B8.92%
2005-12-31โ‚น12.39 B18.91%
2004-12-31โ‚น10.42 B16.61%
2003-12-31โ‚น8.93 B14.21%
2002-12-31โ‚น7.82 B48.26%
2001-12-31โ‚น5.27 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
โ‚น5.037 T 8,614.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น5.135 T 8,784.15%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น6.158 T 10,555.07%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น6.453 T 11,065.83%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น7.034 T 12,071.30%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น9.125 T 15,688.55%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น10.711 T 18,432.04%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น4.31 B-92.54%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น6.10 B-89.43%๐Ÿ‡บ๐Ÿ‡ธ USA